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Squamous cell carcinoma of the head and neck (HNSCC)
arises in the oral cavity, oropharynx, larynx or hypophar-
ynx, and is the 6th leading cause of cancer by incidence
worldwide. Approximately 600,000 cases arise each year,
and only 40-50% of these patients will survive for
5 years.7 HNSCC can express PD-L1 and suppressive
factors that interfere with the differentiation and activa-
tion of dendritic cells and effector function of T cells.
Similar to observations in other malignancies, CD8 effec-
tor T cell infiltration or transcriptional signature consis-
tent with an ongoing T cell response is associated with
prolonged survival. This suggests that HNSCC lacking a
T cell infiltrate may benefit from immune interventions
that induce and/or augment a tumor-specific immune
response. To develop a strategy to address this problem
we have created a HNSCC tumor bank that is cryopreser-
ving enzymatically isolated viable cells from resected
tumors (39 specimens). We are also attempting to
develop primary cell lines (4 lines established) and are
isolating tumor-infiltrating lymphocytes from these
specimens. We are looking to compare immunohisto-
chemical, flowcytometric and functional analyses of these
specimens. Consistent with previous studies, results
document that isolated TIL secrete IFN-g when stimu-
lated with their autologous tumor cells (n=2). Since a
central aim of these studies is to develop a strategy to
create therapeutic immunity in patients lacking T cell
infiltrates, we plan to investigate which antigens are
recognized and whether, antigens present in a novel
DRibble vaccine, that expresses antigens common to
HNSCC, are recognized by these TIL. This may provide
a strategy to monitor anti-tumor immunity in these
patients and possibly provide an antigen source for com-
bination immunotherapy of patients with HNSCC.
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